Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

20030012.LumA

— · A

639bbb08-e048-5a28-a7f3-1a8d751956de

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.600
  • INTERFERON_GAMMA_RESPONSE+0.380
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.360
  • COAGULATION+0.320
  • MYOGENESIS+0.290
  • ALLOGRAFT_REJECTION+0.280
  • PANCREAS_BETA_CELLS+0.270
  • KRAS_SIGNALING_UP+0.250
  • P53_PATHWAY+0.230
  • APOPTOSIS+0.200

Top 10 suppressed

  • E2F_TARGETS-0.690
  • G2M_CHECKPOINT-0.680
  • MYC_TARGETS_V2-0.580
  • MITOTIC_SPINDLE-0.530
  • MTORC1_SIGNALING-0.510
  • MYC_TARGETS_V1-0.500
  • WNT_BETA_CATENIN_SIGNALING-0.420
  • PROTEIN_SECRETION-0.330
  • UNFOLDED_PROTEIN_RESPONSE-0.330
  • SPERMATOGENESIS-0.310

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1C3L-02560
lung-landscapes@6
—cohortA10.900
2TCGA-64-1681-01A-11R-2066-07
lung-landscapes@6
—cohortA10.860
3TCGA-OR-A5L5-01
acc-tcga-pancan-2018@2018
Adrenocortical CarcinomaAdrenocortical Carcinoma, Usual Type0.860
4MNG7
mng-umap@100
——0.856
5TCGA-38-A44F-01A-11R-A24H-07
lung-landscapes@6
—cohortA10.855
6TCGA-44-2661-01A-01R-1107-07
lung-landscapes@6
—cohortA10.855
7TCGA-5L-AAT1-01A-12R-A41B-07
breast-umap@18
—A0.854
8TCGA-50-5055-01A-01R-1628-07
lung-landscapes@6
—cohortA10.854
9SRR1458180
brain-umap@2
GTEX—0.852
10TCGA-BA-A6DB-01A-11R-A30B-07
head-neck@1
——0.851

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 27 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.600Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.380Idelalisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.360Inavolisib— uncovered
COAGULATION0.320Binimetinib— uncovered
MYOGENESIS0.290Inavolisib— uncovered
ALLOGRAFT_REJECTION0.280Idelalisib— uncovered
PANCREAS_BETA_CELLS0.270Cobimetinib— uncovered
KRAS_SIGNALING_UP0.250Inavolisib— uncovered
P53_PATHWAY0.230Idelalisib— uncovered
APOPTOSIS0.200Idelalisib— uncovered
NOTCH_SIGNALING0.200Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.180Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.180Remibrutinib— uncovered
XENOBIOTIC_METABOLISM0.160Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.150Idelalisib— uncovered
KRAS_SIGNALING_DN0.150Remibrutinib— uncovered
ANGIOGENESIS0.130Remibrutinib— uncovered
COMPLEMENT0.100Inavolisib— uncovered
UV_RESPONSE_DN0.100Inavolisib— uncovered
BILE_ACID_METABOLISM0.090Inavolisib— uncovered